Fennec Pharmaceuticals (FRX) Competitors C$8.67 +0.16 (+1.88%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades FRX vs. SLS, TEV, ABT, NOT, PYR, NVO, DNA, VBV, CUS, and AIMShould you be buying Fennec Pharmaceuticals stock or one of its competitors? The main competitors of Fennec Pharmaceuticals include Solaris Resources (SLS), Tervita (TEV), Absolute Software Co. (ABT.TO) (ABT), Noront Resources (NOT), PyroGenesis Canada Inc. (PYR.V) (PYR), Novo Resources Corp. (NVO.V) (NVO), Dalradian Resources (DNA), VBI Vaccines (VBV), Chemtrade Electrochem Inc, (CUS), and Aimia (AIM). These companies are all part of the "pharmaceutical products" industry. Fennec Pharmaceuticals vs. Solaris Resources Tervita Absolute Software Co. (ABT.TO) Noront Resources PyroGenesis Canada Inc. (PYR.V) Novo Resources Corp. (NVO.V) Dalradian Resources VBI Vaccines Chemtrade Electrochem Inc, Aimia Solaris Resources (TSE:SLS) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap basic materials companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, community ranking, analyst recommendations, profitability and risk. Does the media favor SLS or FRX? In the previous week, Fennec Pharmaceuticals had 2 more articles in the media than Solaris Resources. MarketBeat recorded 2 mentions for Fennec Pharmaceuticals and 0 mentions for Solaris Resources. Fennec Pharmaceuticals' average media sentiment score of 0.34 beat Solaris Resources' score of 0.00 indicating that Fennec Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Solaris Resources Neutral Fennec Pharmaceuticals Neutral Is SLS or FRX more profitable? Fennec Pharmaceuticals has a net margin of 5.59% compared to Solaris Resources' net margin of 0.00%. Solaris Resources' return on equity of -148.58% beat Fennec Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Solaris ResourcesN/A -148.58% -51.67% Fennec Pharmaceuticals 5.59%-1,005.59%8.88% Does the MarketBeat Community believe in SLS or FRX? Fennec Pharmaceuticals received 90 more outperform votes than Solaris Resources when rated by MarketBeat users. Likewise, 69.80% of users gave Fennec Pharmaceuticals an outperform vote while only 48.28% of users gave Solaris Resources an outperform vote. CompanyUnderperformOutperformSolaris ResourcesOutperform Votes1448.28% Underperform Votes1551.72% Fennec PharmaceuticalsOutperform Votes10469.80% Underperform Votes4530.20% Which has higher earnings & valuation, SLS or FRX? Fennec Pharmaceuticals has higher revenue and earnings than Solaris Resources. Solaris Resources is trading at a lower price-to-earnings ratio than Fennec Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSolaris ResourcesN/AN/A-C$49.44M-C$0.45-9.84Fennec PharmaceuticalsC$48.89M4.85C$2.73MC$0.1086.70 Do analysts prefer SLS or FRX? Solaris Resources presently has a consensus target price of C$13.50, indicating a potential upside of 204.74%. Given Solaris Resources' higher probable upside, analysts plainly believe Solaris Resources is more favorable than Fennec Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solaris Resources 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Do institutionals & insiders believe in SLS or FRX? 25.1% of Solaris Resources shares are owned by institutional investors. Comparatively, 52.8% of Fennec Pharmaceuticals shares are owned by institutional investors. 40.6% of Solaris Resources shares are owned by insiders. Comparatively, 16.2% of Fennec Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, SLS or FRX? Solaris Resources has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. SummaryFennec Pharmaceuticals beats Solaris Resources on 13 of the 18 factors compared between the two stocks. Ad Porter & CompanyA conspiracy Trump won’t unsealNew documentary reveals the lost wealth-building secret hidden deep within ancient religious texts from almost every civilization… an investment one expert says is “so perfect that only God could have created it.” Watch it now to discover how this asset that you’ve likely never considered before can produce returns so safe, secure, and endless it is nothing short of miraculous.This is the untold, true story of God’s Investment. Get Fennec Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for FRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FRX vs. The Competition Export to ExcelMetricFennec PharmaceuticalsBiotechnology IndustryMedical SectorTSE ExchangeMarket CapC$237.21MC$205.43MC$5.13BC$5.28BDividend Yield2.02%3.50%4.74%5.73%P/E Ratio86.70322.56134.7927.24Price / Sales4.8516,308.331,255.711,070.30Price / Cash11.6611.4540.4180.96Price / Book-173.407.304.903.74Net IncomeC$2.73M-C$18.62MC$117.74MC$276.30M7 Day Performance2.00%183.70%14.56%-1.46%1 Month Performance53.45%172.82%17.54%2.45%1 Year Performance-34.81%127.80%36.48%37.52% Fennec Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FRXFennec PharmaceuticalsN/AC$8.67+1.9%N/A-34.8%C$237.21MC$48.89M86.7010SLSSolaris Resources1.6685 of 5 starsC$4.65+2.4%C$13.50+190.3%+7.0%C$754.42MN/A-10.0910TEVTervitaN/AC$5.81-2.2%N/AN/AC$672.00MC$1.36B-645.5636,800Gap UpABTAbsolute Software Co. (ABT.TO)N/AC$15.22-4.3%N/AN/AC$636.46MC$104.67M63.42115,000High Trading VolumeNOTNoront ResourcesN/AC$1.10-0.5%N/A+0.0%C$612.18MN/A-7.20101,700PYRPyroGenesis Canada Inc. (PYR.V)N/AC$3.85+11.0%N/A+0.0%C$606.96MC$6.01M-154.0090Gap UpNVONovo Resources Corp. (NVO.V)N/AC$2.38-0.4%N/A+0.0%C$548.24MN/A-21.2554,400News CoverageDNADalradian ResourcesN/AC$1.46-0.7%N/AN/AC$519.02MN/A-56.15640VBVVBI VaccinesN/AC$4.82-5.1%N/AN/AC$308.86MC$3.36M-4.9722CUSChemtrade Electrochem Inc,N/AC$1.64-0.6%N/AN/AC$306.50MN/A0.0060News CoverageAIMAimia2.1778 of 5 starsC$2.75+1.1%C$4.00+45.5%-14.6%C$270.55MC$396.20M-2.0520News Coverage Related Companies and Tools Related Companies SLS Competitors TEV Competitors ABT Competitors NOT Competitors PYR Competitors NVO Competitors DNA Competitors VBV Competitors CUS Competitors AIM Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (TSE:FRX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored“The Last Retirement Stock You’ll Ever Need”We've just released a critical trade alert about a groundbreaking AI investment opportunity. So, I wanted t...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fennec Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fennec Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
